Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
The Financial Express12h
Blockbuster weight loss drug Tirzepatide coming to India soon: Benefits, weight loss potential, and side effects
This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...
MarketWatch11h
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and ...
News Medical on MSN2h
Benefits and risks of popular weight-loss drugs revealed
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...
Blockbuster weight-loss drugs linked to lower risk of addiction, schizophrenia, dementia, and more
While weight-loss drugs were linked to lower risk of some conditions, they were also associated with some adverse health ...
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...